Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

Fnu Amisha, Syeda Saba Kareem, Kiranpreet Kaur, Biwei Cao, Samuel Reynolds, Yumeng Zhang, Celeste Bello, Leidy Isenalumhe, Sameh Gaballa, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Javier Pinilla-Ibarz, Lubomir Sokol, Bijal Shah, Frederick Locke, Julio Chavez, Michael Jain

Blood (2025) 146 (Supplement 1): 5512.

https://doi.org/10.1182/blood-2025-5512

Published: 2025

Journal Articles

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

Fatima Tuz Zahra, Ekrem Turk, Najla Al Ali, Sean Haney, Dimitrios Drekolias, Nicole Vincelette, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Eric Padron, Alison Walker, David Sallman, Rami Komrokji, Jeffrey Lancet, Seongseok Yun, Onyee Chan

Blood (2025) 146 (Supplement 1): 291.

https://doi.org/10.1182/blood-2025-291

Published: 2025

Journal Articles

Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy

Blood (2025) 146 (Supplement 1): 4291.

https://doi.org/10.1182/blood-2025-4291

Published: 2025

Journal Articles

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2025-1726

Published: 2025

Journal Articles

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Omar Alzarkali, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2025-3393

Published: 2025

Journal Articles

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Kendra Sweet, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3856.

https://doi.org/10.1182/blood-2025-3856

Published: 2025

Journal Articles

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

Abigail Huetteman, Najla Al Ali, David Sallman, Eric Padron, Andrew Kuykendall, Onyee Chan, Zhuoer Xie, Alison Walker, Seongseok Yun, Samuel Reynolds, Kendra Sweet, Rami Komrokji, Jeffrey Lancet

Blood (2025) 146 (Supplement 1): 3853.

https://doi.org/10.1182/blood-2025-3853

Published: 2025

Journal Articles

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

Rami Komrokji, Amin Azem, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Samuel Reynolds, Seongseok Yun, Alison Walker, Kendra Sweet, Andrew Kuykendall, Jeffrey Lancet, Eric Padron, David Sallman

Blood (2025) 146 (Supplement 1): 3851.

https://doi.org/10.1182/blood-2025-3851

Published: 2025

Journal Articles

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Rami Komrokji, Najla Al Ali, Zena Komrokji, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Kendra Sweet, Jeffrey Lancet, Eric Padron, David Sallman

Blood (2025) 146 (Supplement 1): 2072.

https://doi.org/10.1182/blood-2025-2072

Published: 2025

Journal Articles

Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes

Julie Braish, Najla Al Ali, Zena Komrokji, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 240.

https://doi.org/10.1182/blood-2025-240

Published: 2025

Journal Articles

Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures

Ekrem Turk, Fernando Bustamante, Fatima Tuz Zahra, Yu-Han Chen, Rory Shallis, Onyee Chan, Samuel Reynolds, Alison Walker, Ling Zhang, Seongseok Yun, Jeffrey Lancet, David Sallman, Rami Komrokji, Jinming Song, Eric Padron, Gabriela Hobbs, Andrew Kuykendall, Zhuoer Xie

Blood (2025) 146 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2025-3815

Published: 2025

Journal Articles

Mapping out the impact of MAP kinase in primary myelofibrosis

Samuel Reynolds, Andrew Kuykendall, David Sallman, Gary Reuther, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Alison Walker, Onyee Chan, Seongseok Yun, Eric Padron, Rory Shallis, Jeffrey Lancet, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2025-3812

Published: 2025

Journal Articles

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Onyee Chan, Kendra Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Nardelli, Jatinder Lamba, Jongphil Kim, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Seongseok Yun, Andrew Kuykendall, Eric Padron, Alison Walker, Rami Komrokji, Jeffrey Lancet, David Sallman

Blood (2025) 146 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2025-5216

Published: 2025

Journal Articles

Discontinuation of targeted therapy in histiocytic neoplasms with durable response: A multicenter retrospective study

XI Yang, Haadi Ali, Dana Bossert, Carla Isabel Borre, Brinda H Shukla, Jacquelyn Fitzgerald, Mikaela McDonough, Corbin Wright, Fnu Amisha, Samuel Reynolds, Eric Jacobsen, Eli Diamond, Gaurav Goyal, Jithma Abeykoon, Ronald Go, Asra Ahmed

Blood (2025) 146 (Supplement 1): 726.

https://doi.org/10.1182/blood-2025-726

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Fatima Tuz Zahra, Yumeng Zhang, Sameh Gaballa, Celeste Bello, Samuel Reynolds, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Hayder Saeed, Aleksandr Lazaryan, Abu-Sayeef Mirza, Lubomir Sokol, Bijal Shah, Frederick Locke, Michael Jain, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2025-4555

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes

Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures

Mapping out the impact of MAP kinase in primary myelofibrosis

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Discontinuation of targeted therapy in histiocytic neoplasms with durable response: A multicenter retrospective study

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only